Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia. Landiolol is a selective beta-1 adrenergic ...

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

Credit: Endo, Inc At this time, there have been no reports of adverse events related to this recall. While the blister strips ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The projected costs increased by $2,005,000, $763,000, and $1,164,000 per quality-adjusted life-year gained for expanding HPV vaccination to all mid-adults, those with more lifetime partners, and ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.